Carvykti Shows 50% Five-Year Treatment-Free Remission in Early-Line Myeloma
JNJ sits 54% above its 52-week low of $175.74.
Summary
J&J's Carvykti delivered five-year treatment-free remissions in 50% of patients with early-line relapsed/refractory multiple myeloma, with a 69.2% overall survival rate and median progression-free survival of 60.5 months. This is the first report of these long-term outcomes and strengthens Carvykti's position in an earlier treatment setting, potentially expanding its addressable market. The data could support broader label expansion and competitive differentiation against other CAR-T therapies. J&J shares are trading near their 52-week high, and this positive clinical update may reinforce investor confidence in the oncology pipeline.
At the time of this announcement, JNJ was trading at $270.22 on NYSE in the Life Sciences sector, with a market capitalization of approximately $652.3B. The 52-week trading range was $175.74 to $281.07. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: Reuters.